Failing of the myocardium in patients with dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) is characterized by an upregulation of NADPH oxidase–mediated ROS release associated with increased RAC1 activity (Maack et al., 2003). Here, FMO5 is linked to ischemic cardiomyopathy.